Scripscan:Transgene Biotek Ltd
cmp:35
Code:526139
Story:Transgene Biotek is engaged in the research and development and manufacture of various medical reagents, both chemical and immuno-diagnostic reagents for the qualitative and quantitative estimation of bio-chemical parameters and diagnosis of diseases respectively.Transgene Biotek's net profit galloped 31360% to Rs 15.73 crore on 762.6% growth in net sales to Rs 8.54 crore in Q3 December 2011 over Q3 December 2010. The company said that there was exceptional income of Rs 13.09 crore in Q3 December 2011, which represents gain due to foreign exchange fluctuations.At 235crs marketcap it presents very little excitement.Results are nothing to brag about as its mostly comprises forex gains.Rally in midcaps and strong present momentum in the counter can ignite further price rise in the counter.At about 40 odd one should exit out and move on to something better.
Important Disclaimer&Privacy policy
This blog does not share personal information with third parties nor do we store any information about your visit to this blog other than to analyze and optimize your content and reading experience through the use of cookies.You can turn off the use of cookies at anytime by changing your specific browser settings.This privacy policy is subject to change without notice and was last updated on 20.3.2013. If you have any questions, feel free to contact me directly here: arunsharemarket@gmail.com
Investment in equity shares has its own risks.Sincere efforts have been made to present the right investment perspective.The information contained herein is based on analysis and up on sources that I consider reliable. I,however,do not vouch for the accuracy or the completeness thereof.This material is for personal information and am not responsible for any loss incurred based upon it & take no responsibility whatsoever for any financial profits or loss which may arise from the recommendations above.The stock price projections shown are not necessarily indicative of future price performance.The information herein, together with all estimates and forecasts, can change without notice.
